Funding sources of therapeutic, vaccine clinical trials for Covid

JAMA Network

About The Study: This analysis of 1,977 clinical trials investigating therapeutics and vaccines for COVID-19 found that most were funded by public sources (58%), followed by industry (27%) and public-private partnerships (15%). Most of these clinical trials focused on COVID-19 therapeutics (85%) as opposed to vaccines (15%).

Authors: Elias Mossialos, Ph.D., of the London School of Economics and Political Science, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.26892)

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.